🍂 Enjoy the Fall Season! 🍂
MindTheDesk

Stanford blood cancer transplant therapy reaches first commercial patient

Global - Asia Archived • October 8, 2026 •
Stanford blood cancer transplant therapy reaches first commercial patient
In a remarkable advancement, Stanford researchers have unveiled Orca-T therapy, which has recently received FDA approval. After two decades of rigorous development, this innovative treatment was administered to its inaugural commercial patient, a high-risk leukemia sufferer. Notably, Orca-T significantly minimizes the chances of graft-versus-host disease post-stem cell transplants, offering reduced chemotherapy requirements and lower side effects. Future studies are anticipated to investigate its relevance for broader patient demographics.
Source: Times of India | https://timesofindia.indiatimes.com/rssfeedstopstories.cms - Read Original
"Retirement Health Care"

Discussion (0)

Please log in to post a comment.

No comments yet. Be the first to share your thoughts!

Sponsored
"What you put in is not always what you get out."